Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo

Abstract

Understanding innate immunity is key to improving the safety of adenovirus (Ad) vectors for systemic gene therapy. Ad has been shown to activate complement in vitro, but activation of complement after Ad injection in vivo has not been directly measured. Using complement protein C3a as a marker of complement activation, we show that types 2 and 5 human Ads cause rapid complement activation after intravenous injection in mice. Unexpectedly, the mechanisms in vivo were different than those in vitro. Antibodies were critical for the activation of complement by Ad in vitro, but antibodies were not required in vivo. The classical pathway was required in vitro, whereas complement activation in vivo involved both classical and nonclassical pathways as well as the reticuloendothelial system. Remarkably, the entrydeficient Ad mutant ts1 was completely unable to activate complement in vivo even though it was fully able to activate complement in vitro. This result demonstrates that the complement system senses intravenously injected Ad primarily by detecting the effects of Ad on cells rather than through direct interaction of complement with virions. Encouragingly, shielding Ad with polyethylene glycol was effective at reducing complement activation both in vitro and in vivo. In summary, intravenously injected Ad rapidly activates complement through multiple pathways, but these pathways are different than those identified by in vitro studies. In vitro studies are poorly predictive of in vivo mechanisms because Ad virions activate complement through indirect mechanisms in vivo.

Anti-diabetic properties ofDaphniphyllum macropodumfruit and its active compound

“…The concentrations of drug used in vitro were much higher than maximal plasma concentrations because the mechanisms in vivo were different than those in vitro. [30][31][32] In the present study, we found serum level (96.85 ng/mL) of 5,7-dihydroxychromone after oral administration of DME to be much lower than in the concentrations which achieved in vitro effectiveness on adipocyte differentiation. The in vitro results (Fig.…”

An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood

“…In a recent study, it was shown that antibodies are needed for activation of the classical pathway in vitro in contrast to mice where the major mechanism for complement activation was antibody-independent. 36 Instead of direct recognition of viral particles it was suggested that cell damage induced by adenovirus is the main complement activator in the in vivo situation. In the same study it was shown that PEGylation was able to reduce complement activation in mice.…”

“…In the same study it was shown that PEGylation was able to reduce complement activation in mice. 36 The group of Amalfitano has shown that a functional C3 is needed for adenoviral-induced activation of endothelial cell markers (E-selectin, VCAM and ICAM) and release of several cytokines and chemokines. 37 Thrombocytopenia is a well-known side effect of adenoviral therapy and has been demonstrated to be dependent on C3 and Factor B in mice.…”

Comparative efficacy of dermal fibroblast-mediated and direct adenoviral bone morphogenetic protein-2 gene therapy for bone regeneration in an equine rib model

“…In addition to inflammation, activation of the innate immune response by viral vectors is well confirmed, 22,23 and indeed in horses injected directly with the Ad vector develop detectable serum antibody within weeks. 7 Complicating the potential effectiveness of direct Ad vector delivery would be previous exposure to wild-type adenovirus, the consequence of which would be limited efficacy of the direct vector injection.…”